Iberdomide
Brand names: Zenbexus · Active ingredient: Iberdomide Hydrochloride
In short: ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved un
What is Iberdomide used for?
ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
âš Boxed warning (FDA's strongest warning)
EMBRYO-FETAL TOXICITY
ZENBEXUS is contraindicated in pregnancy. ZENBEXUS is embryo-fetal toxic in animals and can cause birth defects or embryo-fetal death in humans. In females of reproductive potential, obtain 2 negative pregnancy tests before starting ZENBEXUS treatment [Contraindications (4), see Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)].
Females of reproductive potential must use 2 effective forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after last dose of ZENBEXUS treatment [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)].
Because of the risk of embryo-fetal toxicity, ZENBEXUS is only available through a restricted distribution program called ZENBEXUS REMS .
Information about ZENBEXUS REMS is available at www.ZENBEXUSREMS.com or by calling the REMS Call Center at 1-888-423-5436.
SERIOUS VENOUS AND ARTERIAL THROMBOEMBOLISM
Increased risk of deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke in patients with multiple myeloma receiving ZENBEXUS with daratumumab and hyaluronidase-fihj and dexamethasone. Anti-thrombotic prophylaxis is recommended .
Iberdomide dosage
Females of reproductive potential must have negative pregnancy testing and use effective contraception methods before initiating ZENBEXUS .
The recommended dosage of ZENBEXUS is 1 mg orally once daily with or without food on Days 1 to 21 of a 28-day cycle, until disease progression or unacceptable toxicity, in combination with daratumumab and hyaluronidase-fihj and dexamethasone.
The recommended dosage modifications for adverse reactions are provided in Table 1.
Adverse Reaction | SeverityBased on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0. | Dosage ModificationRefer to daratumumab and hyaluronidase-fihj and dexamethasone Prescribing Information for information about dosage modifications for daratumumab and hyaluronidase-fihj and dexamethasone.
Neutropenia (Absolute neutrophil count [ANC] <500 cells/mcL) | Grade 4 | •Interrupt ZENBEXUS.
•Consider initiating granulocyte colony-stimulating factor (GCSF), as appropriate.
•Follow complete blood count (CBC) at least weekly.
•ANC must return to ≥1,000 cells/mcL before restarting.
•The dose of ZENBEXUS may be maintained if neutropenia was the only ZENBEXUS-related toxicity requiring a dose modification and GCSF treatments are continued.
•If a dose reduction is clinically appropriate, decrease ZENBEXUS to 0.75 mg once daily when restarting treatment.
Febrile Neutropenia (ANC <1,000 cells/mcL with a single temperature of >38.3°C [101°F] or with a sustained temperature of ≥38°C [100.4°F] for more than 1 hour) | Grade 3
Thrombocytopenia (platelet count <25,000/mcL) | Grade 4 | •Withhold ZENBEXUS for the remainder of the cycle.
•Platelet count must return to ≥50,000/mcL before restarting.
•Decrease ZENBEXUS to 0.75 mg once daily when restarting treatment.
Thrombocytopenia with bleeding or any requirement for a platelet transfusion | Grade 3
Thromboembolism | ≥ Grade 3 | •Interrupt ZENBEXUS.
•Initiate anticoagulant therapy.
•Restart treatment at a decreased ZENBEXUS dose to 0.75 mg once daily when acute symptoms of thrombosis/embolism have been resolved, at the discretion of the treating physician.
Other ZENBEXUS related adverse reactions | ≥ Grade 3 | •Interrupt ZENBEXUS.
•Restart ZENBEXUS when adverse event has resolved or improved to ≤ Grade 2.
•If a dose reduction is clinically appropriate, decrease ZENBEXUS to 0.75 mg once daily when restarting treatment.
Avoid concomitant use of ZENBEXUS with strong or moderate CYP3A inhibitors.
If concomitant use with strong CYP3A inhibitors is unavoidable, reduce ZENBEXUS dose to 1 mg every other day on Days 1 to 21 of a 28-day cycle .
If concomitant use with moderate CYP3A inhibitors is unavoidable, reduce ZENBEXUS dose to 0.75 mg once daily on Days 1 to 21 of a 28-day cycle . …
How to take Iberdomide — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Embryo-Fetal Toxicity
Advise patients that ZENBEXUS is contraindicated in pregnancy and can cause birth defects or embryo-fetal death in humans .
•Advise females of reproductive potential that they must avoid pregnancy while taking ZENBEXUS and for at least 4 weeks after completing therapy.
•Initiate ZENBEXUS treatment in females of reproductive potential only following two negative pregnancy tests.
•Advise females of reproductive potential of the importance of monthly pregnancy tests and the need to use 2 different forms of contraception, including at least 1 highly effective form, simultaneously during ZENBEXUS therapy, during dose interruption and for 4 weeks after she has completely finished taking ZENBEXUS. Highly effective forms of contraception other than tubal ligation include IUD and hormonal (birth control pills, injections, patch, or implants) and a partner's vasectomy. Additional effective contraceptive methods include latex or synthetic condom, diaphragm, and cervical cap. …
Warnings & precautions
Do not take this medicine if: Based on the mechanism of action and findings in animal studies, ZENBEXUS can cause birth defects or embryo-fetal death in humans . ZENBEXUS is contraindicated in females who are pregnant. Iberdomide causes adverse developmental outcomes in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.
Based on the mechanism of action and findings in animal studies, ZENBEXUS can cause birth defects or embryo-fetal death in humans and is contraindicated for use during pregnancy. Oral administration of iberdomide in pregnant rats and rabbits during the period of organogenesis resulted in adverse developmental outcomes including embryo-fetal mortality, alterations to growth, and structural abnormalities . ZENBEXUS is only available through ZENBEXUS REMS .
Females of reproductive potential must avoid pregnancy while taking ZENBEXUS and for at least 4 weeks after completing therapy.
Advise females of reproductive potential of the potential risk to a fetus and to use 2 methods of effective contraception for at least 4 weeks before beginning ZENBEXUS therapy, during therapy, during dose interruptions and for at least 4 weeks after last dose of ZENBEXUS therapy .
Two negative pregnancy tests with a sensitivity of at least 25 mIU/mL must be obtained prior to initiating therapy. Pregnancy testing should be performed weekly during the first 4 weeks of treatment. Thereafter, testing should occur every 4 weeks in patients with regular menstrual cycles, or every 2 weeks in patients with irregular menstrual cycles .
Females of reproductive potential taking ZENBEXUS must not donate eggs during treatment and for 4 weeks after completion .
ZENBEXUS may pass into human semen. …
Iberdomide side effects
The following clinically significant adverse reactions are described elsewhere in the labeling.
•Serious Venous and Arterial Thromboembolism
•Neutropenia
•Infections
•Second Primary Malignancies
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone was evaluated in EXCALIBER-RRMM, a two-stage, phase 3, randomized, multicenter open-label study in patients with relapsed or refractory multiple myeloma (RRMM) after 1 or 2 prior lines of therapy . Patients were randomized to receive ZENBEXUS (at 1 of 3 dose levels) in combination with daratumumab and hyaluronidase-fihj and dexamethasone or daratumumab and hyaluronidase-fihj, bortezomib and dexamethasone (DVd) in stage 1, and ZENBEXUS 1 mg in combination with daratumumab and hyaluronidase-fihj and dexamethasone (IberDd) or DVd in stage 2. The MRD Primary Analysis Group included the first 420 patients randomized to ZENBEXUS 1 mg in combination with Dd (N=207) or DVd (N=213) in stage 1 and stage 2. Safety was assessed in patients in the MRD Primary Analysis Group who received at least one dose of the study drug (IberDd: N=204; DVd: N=204). …
Drug interactions
Avoid concomitant use of strong or moderate CYP3A inhibitors with ZENBEXUS. If concomitant use cannot be avoided, reduce ZENBEXUS dose .
Iberdomide is primarily metabolized by CYP3A. Concomitant use with strong or moderate CYP3A inhibitors increases iberdomide exposure , which may increase the risk of adverse reactions.
Avoid concomitant use of strong or moderate CYP3A inducers with ZENBEXUS.
Iberdomide is primarily metabolized by CYP3A. Concomitant use with a strong or moderate CYP3A inducer decreases iberdomide exposure , which may decrease efficacy.
About this medicine
ZENBEXUS capsules contain iberdomide hydrochloride, iberdomide is a cereblon-modulating protein degrader. The chemical name of iberdomide hydrochloride is (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione hydrochloride and the chemical structure is as follows:
The molecular formula for iberdomide hydrochloride is C25H27N3O5HCl and the molecular weight is 485.97.
ZENBEXUS capsules contain 0.75 mg or 1 mg of iberdomide (equivalent to 0.81 mg or 1.08 mg respectively of iberdomide hydrochloride) in HPMC capsules and the following inactive ingredients: anhydrous lactose, pregelatinized starch, and stearic acid.
The HPMC capsule shell contain hypromellose, iron oxide black, iron oxide yellow, and titanium dioxide. The 0.75 mg capsule shell also contains iron oxide red. The 0.75 mg capsule is imprinted with white ink that contains povidone, propylene glycol, shellac, sodium hydroxide, and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3663d9cb-3f66-48ae-bf0a-6958bc0888de. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate